5,810 Shares in Jazz Pharmaceuticals PLC $JAZZ Acquired by Point Nemo Capital LLC

Point Nemo Capital LLC purchased a new position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) during the third quarter, Holdings Channel reports. The fund purchased 5,810 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,345,000.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Bank of New York Mellon Corp lifted its holdings in shares of Jazz Pharmaceuticals by 44.5% during the 1st quarter. Bank of New York Mellon Corp now owns 1,679,371 shares of the specialty pharmaceutical company’s stock worth $317,485,000 after acquiring an additional 517,514 shares during the last quarter. Tri Locum Partners LP purchased a new position in Jazz Pharmaceuticals in the first quarter worth $29,995,000. Bank of America Corp DE increased its stake in Jazz Pharmaceuticals by 10.9% in the first quarter. Bank of America Corp DE now owns 1,014,800 shares of the specialty pharmaceutical company’s stock valued at $191,848,000 after acquiring an additional 99,656 shares during the last quarter. Amundi increased its stake in Jazz Pharmaceuticals by 2,445.3% in the first quarter. Amundi now owns 55,640 shares of the specialty pharmaceutical company’s stock valued at $10,519,000 after acquiring an additional 53,454 shares during the last quarter. Finally, Rokos Capital Management LLP bought a new position in Jazz Pharmaceuticals in the first quarter valued at $9,833,000. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Trending Headlines about Jazz Pharmaceuticals

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Jazz beat quarterly estimates, reporting $1.24 billion in revenue versus roughly $1.21 billion expected, with revenue up 10.4% year over year. Coverage also reported that the company raised its 2026 revenue outlook to approximately $4.78 billion–$4.85 billion, helping reinforce the growth outlook. Q3 results and outlook
• Positive Sentiment: RBC, Barclays, Morgan Stanley and JPMorgan issued favorable commentary or raised price targets after the results. The analyst optimism adds support to the stock’s post-earnings momentum. Barclays price-target update
• Neutral Sentiment: CEO Renée Galá sold 1,000 shares under a pre-arranged Rule 10b5-1 plan and retained 140,394 shares. Director Bruce Cozadd also sold 6,000 shares under a pre-arranged plan, while CAO Patricia Carr sold 1,413 shares and retained 6,512. These sales may draw investor attention, but planned transactions are not necessarily a signal about near-term business prospects. Insider transaction coverage

Analyst Upgrades and Downgrades

A number of research firms have weighed in on JAZZ. Stifel Nicolaus set a $275.00 price target on Jazz Pharmaceuticals in a research report on Tuesday, August 4th. Wall Street Zen cut Jazz Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday. UBS Group increased their price objective on Jazz Pharmaceuticals from $315.00 to $337.00 and gave the company a “buy” rating in a research report on Friday, September 11th. JPMorgan Chase & Co. raised their price objective on Jazz Pharmaceuticals from $300.00 to $310.00 and gave the company an “overweight” rating in a report on Tuesday, November 3rd. Finally, Weiss Ratings downgraded Jazz Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Wednesday, October 28th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $293.45.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, EVP Robert Iannone sold 76,921 shares of the company’s stock in a transaction dated Thursday, August 27th. The shares were sold at an average price of $249.70, for a total value of $19,207,173.70. Following the sale, the executive vice president owned 65,686 shares in the company, valued at approximately $16,401,794.20. This represents a 53.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Renée Galá sold 1,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 3rd. The shares were sold at an average price of $225.37, for a total transaction of $225,370.00. Following the transaction, the chief executive officer directly owned 140,394 shares of the company’s stock, valued at $31,640,595.78. This represents a 0.71% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 102,534 shares of company stock valued at $25,185,243. Insiders own 4.10% of the company’s stock.

Jazz Pharmaceuticals Stock Up 3.3%

Shares of NASDAQ:JAZZ opened at $234.76 on Friday. The stock’s 50-day moving average price is $229.39 and its 200-day moving average price is $217.74. Jazz Pharmaceuticals PLC has a 12-month low of $128.80 and a 12-month high of $266.38. The stock has a market capitalization of $15.07 billion, a P/E ratio of 79.85, a price-to-earnings-growth ratio of 0.44 and a beta of 0.38. The company has a current ratio of 1.82, a quick ratio of 1.58 and a debt-to-equity ratio of 1.09.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.03) by $0.15. Jazz Pharmaceuticals had a net margin of 4.37% and a return on equity of 16.88%. The company had revenue of $1.24 billion during the quarter, compared to analyst estimates of $1.21 billion. During the same period last year, the business earned $8.13 EPS. Jazz Pharmaceuticals’s quarterly revenue was up 10.4% compared to the same quarter last year. On average, equities analysts anticipate that Jazz Pharmaceuticals PLC will post 11.08 earnings per share for the current year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing medicines for serious diseases, particularly in neuroscience and oncology. Founded in 2003, the company is headquartered in Dublin, Ireland, and serves patients in the United States and international markets.

Its products include treatments for sleep disorders and seizure conditions, such as Xywav, Xyrem, Sunosi and Epidiolex. Jazz also offers medicines used in cancer care, including Zepzelca, Vyxeos and Rylaze, as well as Defitelio for a serious complication following stem cell transplantation.

Jazz expanded its portfolio through acquisitions, including the 2021 acquisition of GW Pharmaceuticals, which added Epidiolex and other cannabinoid-based medicines.